Progress in treatment of spinal metastases of prostate cancer

doi:10.3877/cma.j.issn.1673-9450.2019.03.014

Abstract

Abstract:

Spinal metastasis is one of the common complications of prostate cancer. Skeletal related event (SRE) caused by spinal metastases seriously affect patients′ quality of life, increase the risk of death. There is no standard treatment for spinal metastasis of prostate cancer. This paper briefly describes the advance of radiotherapy, surgery and support care, bone targeted agents for spinal metastases of prostate cancer. The authors think that the treatment of spinal metastases strategy should be interdisciplinary and individualized.

Key words: Prostatic neoplasms, Spine, Neoplasm metastasis, Surgical procedures, operative, Radiotherapy

Weigang Jiang, Wei Sun, Yaosheng Liu, Shubin Liu. Progress in treatment of spinal metastases of prostate cancer[J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2019, 14(03): 231-234.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhssyxfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1673-9450.2019.03.014

https://zhssyxfzz.cma-cmc.com.cn/EN/Y2019/V14/I03/231

References 32

[1]	Zairi F, Marinho P, Bouras A, et al. Recent concepts in the management of thoracolumbar spine metastasis[J]. J Neurosurg Sci. 2013, 57(1): 45-54.
[2]	贾连顺，陈江华. 脊柱转移瘤外科诊断治疗的现状与进展[J]. 中华骨科杂志，2003, 23(6): 331-334.
[3]	Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007[J]. CA Cancer J Clin, 2007, 57(1): 43-66.
[4]	Lutz S, Lo SS, Chow E, et al. Radiotherapy for metastatic bone disease: current standards and future prospectus[J]. Expert Rev Anticancer Ther, 2010, 10(5): 683-695.
[5]	Chow E, Zeng L, Salvo N, et al. Update on the systematic review of palliative radiotherapy trials for bone metastases[J]. Clin Oncol, 2012, 24(2): 112-124.
[6]	Yoon F, Morton GC. Single fraction radiotherapy versus multiple fraction radiotherapy for bone metastases in prostate cancer patients: comparative effectiveness[J]. Cancer Manag Res, 2014, 6: 451-457.
[7]	Rades D, Stalpers LJ, Veninga T, et al. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression[J]. J Clin Oncol, 2005, 23(15): 3366-3375.
[8]	Harel R, Zach L. Spine radiosurgery for spinal metastases: indications, technique and outcome[J]. Neurol Res, 2014, 36(6): 550-556.
[9]	Lo SS, Sahgal A, Wang JZ, et al. Stereotactic body radiation therapy for spinal metastases[J]. Discov Med, 2010, 9(47): 289-296.
[10]	Chawla S, Schell MC, Milano MT. Stereotactic body radiation for the spine: a review[J]. Am J Clin Oncol, 2013, 36(6): 630-636.
[11]	Bate BG, Khan NR, Kimball BY, et al. Stereotactic radiosurgery for spinal metastases with or without separation surgery[J]. J Neurosurg Spine, 2015, 22(4): 409-415.
[12]	Cunha MV, Al-Omair A, Atenafu EG, et al. Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy(SBRT): analysis of predictive factors[J]. Int J Radiat Oncol Biol Phys, 2012, 84(3): 343-349.
[13]	Thibault I, Al-Omair A, Masucci GL, et al. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture[J]. J Neurosurg Spine, 2014, 21(5): 711-718.
[14]	Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases: a systematic review[J]. J Clin Oncol, 2007, 25(11): 1423-1436.
[15]	Parker CC, Pascoe S, Chodacki A, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer[J]. Eur Urol, 2013, 63(2): 189-197.
[16]	雷明星，刘蜀彬，郑文静，等. 脊柱转移瘤外科治疗原则[J/CD]. 中华损伤与修复杂志(电子版), 2017, 12(3): 207-211.
[17]	Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial[J]. Lancet, 2005, 366(9486): 643-648.
[18]	Lee CH, Kwon JW, Lee J, et al. Direct decompressive surgery followed by radiotherapy versus radiotherapy alone for metastatic epidural spinal cord compression: a meta-analysis[J]. Spine, 2014, 39(9): E587-E592.
[19]	Crnalic S, Hildingsson C, Wikström P, et al. Outcome after surgery for metastatic spinal cord compression in 54 patients with prostate cancer[J]. Acta Orthop, 2012, 83(1): 80-86.
[20]	Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial[J]. Lancet Oncol, 2011, 12(3): 225-235.
[21]	Coxon FP, Rogers MJ. The role of prenylated small GTP-binding proteins in the regulation of osteoclast function[J]. Calcif Tissue Int, 2003, 72(1): 80-84.
[22]	Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group[J]. J Clin Oncol, 2003, 21(16): 3150-3157.
[23]	Winquist E, Berry S. Re: A Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma[J]. J Natl Cancer Inst, 2004, 96(15): 1183.
[24]	Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma[J]. J Natl Cancer Inst, 2002, 94(19): 1458-1468.
[25]	Wirth M, Tammela T, Cicalese V, et al. Prevention of bone metastases in patients with high-risk non metastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS)[J]. Eur Urol, 2015, 67(3): 482-491.
[26]	Smith MR, Halabi S, Ryan CJ, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)[J]. J Clin Oncol, 2014, 32(11): 1143-1150.
[27]	Brown JE, Coleman RE. Denosumab in patients with cancer-a surgical strike against the osteoclast[J]. Nat Rev Clin Oncol, 2012, 9(2): 110-118.
[28]	Dougall WC, Holen I, González Suárez E. Targeting RANKL in metastasis[J]. Bonekey Rep, 2014, 3: 519.
[29]	Lipton A, Fizazi K, Stopeck AT, et al. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics[J]. Eur J Cancer, 2016, 53: 75-83.
[30]	Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study[J]. Lancet. 2011, 377(9768): 813-822.
[31]	Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial[J]. Lancet, 2012, 379(9810): 39-46.
[32]	Smith MR, Saad F, Oudard S, et al. Denosumab and bone metastasis-free survival in men with non metastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time[J]. J Clin Oncol, 2013, 31(30): 3800-3806.

Please choose a citation manager

Content to export